Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PYPD
SELLPolyPid Ltd. · Healthcare · Israel · $75M · Avg Vol: $1M/d
COMPANY DESCRIPTION
PolyPid Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted, localized therapeutics. The company's competitive moat is its proprietary PLEX (Polymer-Lipid Encapsulation Matrix) technology, which enables the controlled, prolonged release of drugs directly at the surgical site. Its lead product candidate targets the prevention of surgical site infections, positioning the company as a niche player in post-operative care.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 15.0M | 8.6M | — |
| EPS | -2.10 | -1.47 | -4.91 | -2.09 | — | -1.74 | -1.43 | -1.26 | — |
| Shares | 19.2M | 19.2M | 10.2M | 18.2M | -5.1% | 19.2M | — | — | — |
| Debt | 13.7M | 11.8M | 9.6M | 2.8M | -41.2% | 2.3M | — | — | — |
| Equity | 5.8M | -2.1M | 7.7M | 11.0M | 23.5% | — | — | — | — |
| Op CF | -34.3M | -17.2M | -22.0M | -27.9M | — | — | — | — | — |
| Inv CF | 16.6M | 3.8M | -0.3M | -6.7M | — | — | — | — | — |
| Fin CF | 16.4M | 10.0M | 32.4M | 25.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PYPD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PYPD | PolyPid Ltd.(you) | $75M | 21 | SELL |
| ENTX | Entera Bio Ltd. | $101M | 17 | STRONG SELL |
| ENLV | Enlivex Ltd. | $71M | 12 | STRONG SELL |
| MDWD | MediWound Ltd. | $183M | 8 | STRONG SELL |
| SLGL | Sol-Gel Technologies Ltd. | $268M | 33 | SELL |
| DRTS | Alpha Tau Medical Ltd. | $1.1B | 26 | SELL |
| CGEN | Compugen Ltd. | $216M | 98 | STRONG BUY |
| NNOX | Nano-X Imaging Ltd. | $62M | 8 | STRONG SELL |
| INCR | InterCure Ltd. | $55M | 36 | HOLD |
| BVC.L | BATM Advanced Communications Ltd. | $67M | 51 | HOLD |
Peer medians: ROE 5.1% · P/E 16.5x · Gross margin 36.8%